# Pharmacogenetics, Emotional Reactivity and Smoking

> **NCT00507728** · PHASE2,PHASE3 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 646 (actual)

## Conditions studied

- Tobacco Use Disorder
- Smoking Cessation

## Interventions

- **DRUG:** Bupropion
- **DRUG:** Varenicline
- **DRUG:** Placebo
- **BEHAVIORAL:** Smoking Cessation Counseling

## Key facts

- **NCT ID:** NCT00507728
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12-08
- **Primary completion:** 2019-12-18
- **Final completion:** 2019-12-18
- **Target enrollment:** 646 (ACTUAL)
- **Last updated:** 2021-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00507728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00507728, "Pharmacogenetics, Emotional Reactivity and Smoking". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00507728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*